VivoSense recently contributed to pivotal discussions at the 11th Annual Mobile in Clinical Trials and the 14th Annual DPHARM conferences in Philadelphia. Both events, known for championing advancements in clinical trials, focused this year on patient engagement, operational efficiency, and demonstrating ROI through the adoption of Digital Health Technologies (DHTs).
Our VP of Commercial Strategy, Rob Wilson, joined two influential panels at these events, sharing insights on DHT implementation.
Disrupting Evidence Generation at DPHARM
Rob participated in the panel titled “Disrupting the Evidence Generation Paradigm: Driving Greater Adoption of DHTs and Endpoints in Clinical Trials,” moderated by Kimberly Barnholt, PhD, MS, Executive Director and Evidence Generation Leader at Genentech. Panelists included:
- a. Felix Lee, MBA – US Digital Healthcare Medical Head, Sanofi
- b. Gillian Livock – Chief Growth Officer, Evinova
- c. Katie Madden, PMP – Director of Digital Health Optimization, Global Clinical Operations, GSK
View DPHARM 2024 Recap Here
Wearable Integration in Clinical Trials at Mobile in Clinical Trials
Rob also contributed to a discussion led by Stephen Ruhmel, MPH, Clinical Strategy Lead for Digital Endpoints at Sanofi. This session explored the integration of wearable devices, novel endpoints, and digital biomarkers. Panelists included:
- a. Nishit Agarwal – Medidata
- b. Bharat Koyani – Regeneron
- c. Katerina Placek, PhD – Takeda
- d. Hao Zhang, PhD, MBA – Mitsubishi Tanabe Pharma America
View Mobile in Clinical Trials 2024 Recap Here
Key Takeaways
- • Patient-Centric Approach: Successful DHT adoption hinges on prioritizing patient-friendly technology that minimizes burden.
- • Change Management for Innovation: A focused approach within Sponsors and CROs is essential to navigate the highly regulated industry landscape.
- • ROI Metrics and Validation: Tufts CSDD and DiMe’s projects are shaping the ROI standards needed for broader DHT implementation.
- • FDA Support and Guidance: Early communication between sponsors and regulators remains critical for aligning on regulatory clarity and fostering innovation.
With these insights, VivoSense continues to advance the integration of digital tools in clinical trials, driving a future where DHTs enable more effective and patient-centric care.